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Abstract
Background: APOBEC3G is an antiretroviral factor that acts by inducing G to A mutations. In
this study, we examined the expression of APOBEC3G in uninfected HIV-1 exposed individuals at
the time of their partner's diagnosis and one year later. We then compared this expression with
that of infected individuals at different disease stages. APOBEC3G mRNA was measured in PBMCs
from three groups: healthy controls with no known risk factor to HIV infection (n = 26), exposed
uninfected individuals who had unprotected sex with their HIV+ partners for at least 3 months (n
= 37), and HIV infected patients at various disease stages (n = 45), including 8 patients with low
HIV viral loads < 10,000 copies/mL (LVL) for at least 3 years. Additionally, we obtained sequences
from the env, gag, pol, nef, vif and the LTR of the patients' virus.
Results: Exposed uninfected individuals expressed higher APOBEC3G than healthy controls (3.86
vs. 1.69 relative expression units), and their expression significantly decreased after a year from the
HIV diagnosis and subsequent treatment of their partners. Infected individuals showed a positive
correlation (Rho = 0.57, p = 0.00006) of APOBEC3G expression with CD4+ T cell count, and a
negative correlation with HIV viremia (Rho = -0.54, p = 0.00004). The percentage of G to A
mutations had a positive correlation (Rho = 0.43, p = 0.0226) with APOBEC3G expression, and it
was higher in LVL individuals than in the other patients (IQR 8.27 to 9.64 vs. 7.06 to 8.1, p =
0.0084). Out of 8 LVLs, 3 had hypermutations, and 4 had premature stop codons only in viral vif.
Conclusion: The results suggest that exposure to HIV may trigger APOBEC3G expression in
PBMCs, in the absence of infection. Additionally, cessation of exposure or advanced disease is
associated with decreased APOBEC3G expression.
Background
Human APOBEC3G (hA3G) is a cellular antiretroviral fac-
tor with a potent inhibitory effect on HIV replication. The
cytidine deaminase activity of hA3G catalyses the conver-
sion of cytosine to uracil on the negative-strand viral
cDNA[1]. In vitro, hA3G inhibits HIV replication by caus-
ing G to A hypermutations, preferentially in the GG dinu-
cleotide context. These mutations often alter the amino
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acid sequences of multiple viral gene products and intro-
duce lethal stop codons, thereby compromising HIV rep-
lication [2-4]. In contrast, APOBEC3F acts preferably in
the GA context. In addition to G to A hypermutation,
other h3AG antiretroviral mechanisms have been pro-
posed, which include interaction with the HIV nucleocap-
sid with subsequent inhibition of tRNALys3 annealing to
viral RNA, and DNA strand transfer during reverse tran-
scription [2,3]. Recently, studies in murine models suggest
a link between hA3G and virus-specific neutralizing anti-
body responses in Friend Virus (FV) infection[4]. As a
countermeasure to hA3G restriction, HIV-1 neutralizes
the antiretroviral activity of hA3G by inducing its ubiqui-
tination and degradation through the Vif protein [5-7]. In
vivo, the significance of hA3G-induced hypermutation as
a protecting agent of clinical pathogenesis and HIV dis-
ease progression remains uncertain. One study suggested
that hA3G mRNA levels in activated PBMCs correlated
negatively with plasma HIV RNA levels and positively
with CD4+ T cell counts[8]. In contrast, a different
research group did not find any correlation[9]. On the
other hand, one report showed significantly increased
hA3G mRNA in PBMCs and cervical biopsy cells from
HIV-exposed seronegative individuals (ES)[10], and a sep-
arate report found that stimulated PBMCs of long term
non-progressors (LNTP) had significantly higher hA3G
mRNA levels than either uninfected controls or individu-
als with progressive HIV disease[8]. Finally, Ulenga et
al[11] found that patients with a low viral set point had a
higher hA3G expression than patients with high viral set
point. Taken together, these studies point to an in vivo
HIV neutralizing activity of hA3G.
All the above reports were carried out in different patient
groups and experimental conditions, which preclude
direct comparisons about differential expression levels
between groups like LTNP and ES. Additionally, the ques-
tion remains whether hA3G is constitutively expressed by
these protected patients, or whether its expression is the
result of exposure to HIV or its gene products. To address
this question, we measured hA3G mRNA expression in
unstimulated PBMCs from an ES cohort at the time of first
diagnosis of their sexual partners, and after one year of
antiretroviral treatment of the infected partner, in order to
observe if the expression levels varied with the decrease in
viremia of their partners, or remained unchanged. The
findings would indicate either induced or constitutive
hA3G expression, respectively. In parallel, we contrasted
these results with hA3G mRNA expression in HIV infected
persons at different disease stages and correlated the
expression levels with CD4+ counts and HIV viral load.
Separately from these patients, we also studied a subgroup
of 8 subjects (low viral load group, LVL) that had
remained with HIV viral load < 10,000 copies/mL for at
least three years, in order to assess if a sustained control of
viremia was related to hA3G expression. Additionally, we
measured G to A mutation activity on the viral vif, gag, pol,
nef, env and LTR sequences from 20 randomly selected
patients. We also included twenty six healthy subjects (HC
group), with no known HIV risk factors as a control group
for this study.
Results
hA3G mRNA expression in ES, HC and HIV infected 
patients at different stages of disease
Median hA3G mRNA levels were significantly increased in
the PBMCs from ES individuals and LVL individuals as
compared to HC and HIV+ patients (Figure 1). We did not
find a statistical difference between median hA3G mRNA
levels in ES subjects and LVL patients. In HIV+ patients we
found a significantly positive correlation between hA3G
expression and peripheral blood CD4+ cell count (Figure
1). The overall hA3G mRNA expression was significantly
lower in the HIV+ patients than in the HC, ES and LVL
individuals (Figure 1), which was expected given the cor-
relations mentioned above and that HIV+ patients had a
relatively advanced disease stage (median CD4+ 265, IQR
45.75 to 480.25).
We found a negative correlation between plasma viral
load and hA3G expression (Rho = -0.54, p = 0.00004), as
can be seen in Figure 2.
hA3G mRNA expression in ES after one year of partner's 
diagnosis
To examine if the high hA3G mRNA expression in ES was
constitutive or if it was induced by exposure to HIV anti-
gens, we measured the hA3G mRNA expression in 12 ran-
domly selected ES individuals after one year of diagnosis
of their partners (Figure 3, left panel). In all the examined
ES individuals, the level of hA3G expression decreased
(Wilcoxon sign test p = 0.0022), and reached comparable
levels to healthy controls (Figure 3, left panel, box plot
inset). In addition, we were able to gather information
from some partners of ES individuals that still remained
as couples, and collected data on 9 basal samples and 8
samples after a year. Using these samples, we measured
the change in their viral loads after a year of antiretroviral
treatment. The other 3 ES partners were treated at different
institutions, and we did not have access to their data. As
can be seen in Figure 3, right panel, all but one infected
partner (who reduced from > 750,000 to 194,000) had
undetectable HIV levels after a year. The overall reduction
was also significant (Wicoxon's sign test p = 0.018).
Detection of G to A mutation and hypermutation in HIV 
sequences
In order to test if a high expression of hA3G mRNA corre-
lated with an increased anti- HIV activity, we analyzed the
number of G to A mutations in the gag, pol, env, nef, vifRetrovirology 2009, 6:23 http://www.retrovirology.com/content/6/1/23
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and LTR sequences from 20 randomly selected LVL and
HIV+ individuals. LVL patients had a higher percentage of
hA3G-type G to A mutations from the total G content in
the analyzed sequences than the rest of the infected
patients, with a median value of 8.86% vs. 7.9% (IQR
8.27 to 9.64 vs. 7.06 to 8.1, p = 0.0084, Mann-Whitney's
U). Additionally, we found a significant correlation
between the level of hA3G mRNA expression and the per-
centage of G to A mutations (Rho = 0.43, p = 0.0226).
There were no significant differences in the percentage of
G to A mutations between the different viral genes. Direct
sequencing of HIV amplicons revealed hypermutations in
only 3 LVL HIV sequences, and they resided only in the vif
region (Figure 4). Two occurred in the GGcontext (charac-
teristic of hA3G activity), and one occurred in the GAcon-
text (characteristic of hA3F activity). In order to identify
probable Vif mutants that selectively failed to efficiently
"silence" hA3G enzymes in LVL individuals, we looked for
premature stop codons in vif  sequences from these
patients (Figure 4). Three out of eight vif sequences in LVL
contained one or more premature stop codons in the con-
text of a Trp codon (TGG to TAG). No stop codons were
found in vif sequences of HIV+ individuals that were not
LVL. Motifs SQLYLAL and Y40RHHY44, which are essential
for ubiquitination and interaction with hA3G, respec-
tively [12,13], were totally conserved in all sequences. We
did not observe hypermutations or premature stop
codons in the gag, pol, nef, env or LTR regions of HIV.
Discussion
The role of hA3G in regulating HIV replication in vivo is
unclear. In this study, we demonstrated that individuals
hA3G mRNA expression in ES, HC and HIV infected patients at different stages of disease Figure 1
hA3G mRNA expression in ES, HC and HIV infected patients at different stages of disease. Results for log hAG3 
mRNA expression in healthy control subjects, exposed seronegative individuals, HIV+ patients that have consistently low viral 
loads (LVL) < 10,000 copies/μL for at least 3 years, and typical progressors. Typical progressors are shown as a regression 
over CD4+ cell/μL, with Spearman's Rho and significance marked. Horizontal lines show the median, sloped solid line is the lin-
ear regression, and the flanking dashed lines show the 95% confidence interval for the mean. Horizontal lines with arrows 
show the significant differences between groups (Mann-Whitney's U test).Retrovirology 2009, 6:23 http://www.retrovirology.com/content/6/1/23
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exposed to HIV, either through unprotected sex with an
infected partner or during a non-AIDS phase of HIV infec-
tion, have an increased expression of hA3G mRNA, as
shown directly by the expression levels in ES individuals,
and by the positive correlation between CD4+ cell count
and hA3G mRNA expression. Once the virus overcomes
the immune system of the patient, hA3G mRNA expres-
sion is almost completely suppressed. This can be seen by
the negative correlation between hA3G mRNA expression
and HIV plasma viral load, and by the lower hA3G mRNA
expression seen in the advanced HIV+ patients.
Further supporting the notion that hA3G mRNA expres-
sion is related to exposure to HIV gene products, the
viremia levels of the ES's partners were significantly
reduced a year after HIV diagnosis and subsequent antiret-
roviral treatment, coinciding with a reduction in hA3G
mRNA expression in the ES subjects. The dramatic reduc-
tion in plasma HIV viral load most probably reduced
exposure of ES subjects to the viral gene products of their
partners. An additional reduction of exposure to HIV gene
products would result if the ES individuals adopted safer
sex practices, and it is reasonable to assume that at least
some of the ES initiated these safer sex practices after
being informed of their partner's diagnosis. Even though
we cannot fully document a lack of further HIV exposure
in our ES cohort, this notion appears to be the best expla-
nation for the reduction in hA3G mRNA expression in the
ES individuals.
In this study, we found increased levels of hA3G mRNA in
the unstimulated PBMCs of two groups in the same
cohort: exposed seronegative and LVL individuals. These
increased hA3G mRNA levels are in agreement with previ-
ous reports that examined CD3 and CD28-stimulated
PBMCs in long term non-progressors[8] and in ES indi-
viduals[10]. Here we found that ES and LVL groups have
similar values of hA3G mRNA expression, which may sug-
gest that ES individuals regulate hA3G in a similar manner
as LVL patients.
The negative correlation of hA3G expression with viremia
described in the present study (Figure 2) is in agreement
with and clarifies other reports. Jin et al[14] have specu-
lated that HIV infection can induce different discrete
stages of hA3G expression, which is in concordance with
our findings. Additionally, Ulenga et al. [11] recently
reported that patients with a higher viral set point
expressed less hA3G and hA3F mRNAs than low viremic
set point patients, also suggesting that hA3G expression is
suppressed in advanced disease.
Jin et al[14] suggested that the observed discrete stages of
hA3G expression arise by naturally selecting from the gen-
eral population individuals that constitutively express
high levels of hA3G. Our data do not support this conten-
tion, since the ES individuals decreased their hA3G mRNA
expression after a year of their partners' diagnoses and
treatment, and return to healthy control levels, which sug-
gested that they had the same constitutive hA3G expres-
sion than that of the general population, but that they
induced this expression after coming into contact with
HIV gene products. However, there is a high degree of var-
iability in the hA3G mRNA expression in the ES individu-
als, and there are suggestions that expression may be
bounded[14], so that the final level of expression is the
result of the contributions from host genetic susceptibility
and the amount of HIV exposure. It remains to be studied
if the ES individuals have a genetic susceptibility to have a
higher or faster induced expression to initial HIV expo-
sure, and this is what conferred to them their apparent
immunity.
The present methodology cannot definitively assess if the
reduction in hA3G mRNA in PBMCs is the result of a
larger proportion of hA3G expressing cells or an increase
in hA3G expression at the single cell level. However, the
fact that ES subjects had similar CD4+, CD8+ T cells and
monocyte PBMC composition at the basal and one year
measurements (data not shown) suggests that the differ-
ent expression levels are reflected at the single cell level.
Furthermore, it has been established that ES individuals
can generate anti-HIV-1 T cell responses while remaining
uninfected, but lose these responses after ceasing exposure
to HIV[15]. T cells produce interleukin-2 (IL-2) in
response to stimulation by synthetic HIV-1 env-derived
peptides, and Stopak et al. have observed that IL-2 and IL-
15 activated de novo hA3G gene expression in primary
Relationship between log hA3G mRNA expression with log  viral load Figure 2
Relationship between log hA3G mRNA expression 
with log viral load. The sloped solid line is the linear 
regression, and the flanking dashed lines show the 95% confi-
dence interval for the mean (Rho = -0.5418, p = 0.00004). 
Solid dots represent subjects with persistent < 10,000 cop-
ies/mL for more than 3 years, and the open dots are typical 
progressors.Retrovirology 2009, 6:23 http://www.retrovirology.com/content/6/1/23
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PBMCs[16]. Thus, the secretion of these cytokines could
explain the increased levels of hA3G mRNA in ES individ-
uals.
The mutation data obtained from the 20 individuals
showed a significant correlation between the percentage
of G to A mutation and hA3G mRNA levels and a higher
G to A mutation rate in the LVL subjects. Potentially dys-
functional hypermutated regions were found in three
sequences, and four sequences had premature stop
codons. This incidence of hypermutated sequences did
not correlate with hA3G mRNA expression, as was
reported elsewhere [17]. This is possibly due to differences
in the sample size and the length of the sequences ana-
lyzed. Taken together, the data suggest that the expression
of hA3G mRNA is associated with the telltale signs of
APOBEC3 activity on the viral genome.
Pillai et al. have hypothesized that there is a dose-depend-
ent response between intracellular hA3G concentrations
and the degree of viral hypermutation[18]. Also, they
assumed that while an effective inhibition of vif  may
result in mutational extinction, weak inhibition may
accelerate evolution of drug resistance, and immune
escape. Our data do not shed light on ether a mutational
extinction or accelerated evolution.
Chiu et al. [19] reported a distinction between the active
low molecular weight form (LMW) of hA3G and its inac-
tive high molecular weight form (HMW). In this regard
Stopak et al. [16] had demonstrated that activation by
cytokine treatment induced a shift of LMM hA3G to its
HMM conformation, paralleled by an increase in suscep-
tibility to HIV infection. On the other hand, Vif could also
induce conformational changes of hA3G into HMM com-
plexes [20,21]. With the methodology described here, we
cannot quantify how much mRNA will be translated into
LMM or HMM forms, which could be important for viral
control. However, we could observe that APOBEC3-like
action on the viral genomes correlated with mRNA expres-
sion. This could be due to LMM forms induced in den-
dritic cells [15].
Recently one report showed that HIV hypermutations cor-
related with CD4+ counts [22]; however, we did not find
this correlation, and we only found an increased G to A
mutation rate, without reaching a statistically significant
hypermutated score. In conclusion, our study shows that
levels of hA3G mRNA are increased in ES individuals and
in early stages of HIV infection, while the levels are
decreased a year after their partners' diagnoses and treat-




The study sample consisted of 108 subjects. 26 were
healthy controls (HC) free of HIV risk factors, screened
with a blood donation questionnaire. 37 were HIV-
exposed seronegative individuals (ES) and had a history
of multiple unprotected sexual episodes within three
months before entering the study. The continued seroneg-
ative status was verified for at least one year with subse-
quent serum samples analyzed by ELISA. Additionally,
they were tested for the presence of HIV DNA in PBMCs
by gag and LTR nested PCR [23]. 45 were infected patients
hA3G mRNA expression in ES after one year ofexposure Figure 3
hA3G mRNA expression in ES after one year ofexposure. Left panel. hA3G mRNA expression in exposed seronega-
tive subjects at time of diagnosis of their partners, and after one year of follow up. There was a significant decrease (p = 0.0022, 
Wilcoxon sign test). The inset box plot is healthy control expression level, for reference purposes only. Right panel. Viral load 
in the partners of the ES subjects after a year of treatment. The overall reduction was also significant (Wicoxon's sign test p = 
0.018).Retrovirology 2009, 6:23 http://www.retrovirology.com/content/6/1/23
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Analysis of complete vif sequences derived from 20 different HIV+ individuals Figure 4
Analysis of complete vif sequences derived from 20 different HIV+ individuals. Graphical representation of the G to 
A changes compared with HIV HXB2 reference. The nucleotide context GG, GA, GC or GT represents two contiguous bases, 
with G to A mutations occurring in the first base. hA3G mRNA levels are shown on the left column and significant hA3G-type 
hypermutations on the right column. The three significantly hypermutataded sequences are from patients having < 10,000 viral 
copies/mL for over three years.Retrovirology 2009, 6:23 http://www.retrovirology.com/content/6/1/23
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without antiretroviral treatment (HIV+) and were at dif-
ferent disease stages, with a median of 305 CD4+ cells/μL
(IQR 53.25 to 535). These included 8 individuals with
low viral loads (LVL), < 10,000 HIV-1 RNA copies/mL for
at least three years of follow-up and who were naive to
antiretroviral therapy. This study was approved by the
Bioethics and Research Committee of the National Insti-
tute of Respiratory Diseases, Mexico, and all patients and
subjects read and signed informed consent letters.
Relative expression of hA3G mRNA
Peripheral venous blood samples were collected in EDTA
tubes; PBMCs were separated by Ficoll density gradient
and stored at -80°C. DNA and total RNA was extracted
from PBMCs by QIAGEN Blood minikit and RNeasy
minikit (Qiagen, Valencia, CA, USA), respectively.
To measure hA3G mRNA expression, cDNA products were
first synthesized from the total RNA with random primers
using a Transcriptor First Strand cDNA Synthesis Kit
(Roche Diagnostics, Mannheim, Germany). cDNA quan-
tification for hA3G and G6PDH (LightMix, for the detec-
tion of human G6PDH, Roche) was performed by real
time PCR using FastStart DNA Master Hybprobes and
LightCycler thermal cycler 2.0 (Roche). Primer and hyb-
probe design were specific for hA3G (NM 021822), hu
ApoB 3G F2 (CAATAATGACATACAGTGAATTT), hu ApoB
3G R2 (CAGGTCTCTGCCTTCCTTAGA), huApoB3GFL
(GACATCCCTGGTGGTCCACA-FL) and hu ApoB 3G LC
(LC640-GGTGTCCCAGCAGTGCTTAAA-PH). For each
sample, the number of copies of hA3G mRNA was divided
by the number of copies of G6PDH mRNA, in order to
normalize for hA3G mRNA expression in different cell
samples. Relative expression units were calculated as
expression of hA3G/expression of G6PDH. The results are
given as median relative expression units of triplicate
assays.
Statistical analysis
All statistical analyses were carried out with R statistical
programming environment[24] version 2.7.1. Statistical
differences between groups were assessed with Mann-
Whitney U test, correlations were calculated with Spear-
man's rho, and paired before-after comparisons were car-
ried out with Wilcoxon's signed rank test. hA3G mRNA
expression is shown in figures as a logarithm, since it was
derived from a ratio, and was therefore log-normal. This
transformation did not affect the results of the statistical
tests, since they relied on the ranks of the data.
Determination of hypermutated sequences
We amplified and sequenced 5 different regions of HIV
proviral DNA: P2, P7, P1 and P6 (gag), protease and RT
(pol), V3 loop (env), and the entire vif and nef genes. nef
and the V3 loop were amplified as previously
reported[25,26]. Protease and RT sequences were ampli-
fied and analyzed by a Viroseq kit (Celera Diagnostics,
Alameda, CA, USA). P2, P7, P1 and P6 of gag and the
entire  vif  gene were amplified by nested PCR. Initial
amplification of gag  was performed using primers
p2p7p1p6F outer (5'A TTGG AT GACA GAAAC CTT GTT
GG3') and p2p7p1p6R outer (5'C TTCT AATACTG
TATCATCTGCTCC3'),  vif  initial amplification was per-
formed using primers JVPvifF (5'ACAG CAGA GATCCA
CT3') and JVPvifR2 (5'AGAATTCTTATTATGGCTTCCA 3')
. An aliquot (5 μL) of first round PCR product was then
used as a template in a second PCR reaction with primers
p2p7p1p6F inner (5'GAAGAAATGATGACAGCATGTC3')
and p2p7p1p6R inner (5'C ATCT GCTCCT GTATCT
AATAG3'), and JVPvifF2 (5'T GG AAAGG ACCAG
CAAAGCT3') and JVPvifR (CTAGGAAAATGTCTAACAGC
TT), respectively. We used High Fidelity Polimerase (Plat-
inum Taq DNA Polymerase High Fidelity, Invitrogen,
Carlsbad, California, United States) in all PCR reactions.
Nucleotide sequences of PCR products were determined
using BigDye Terminator cycle sequencing kit (Applied
Biosystems) and ran on an ABI Prism 3100 analyzer
sequencer (Applied Biosystems). Nucleotide sequences of
PCR products were aligned and analyzed using Clustal
X[27] and MEGA 4.0[28] respectively. Analysis of G to A
substitution in proviral sequences was performed using
HYPERMUT 2.0 with default settings, available from
http://www.hiv.lanl.gov/content/sequence/HYPERMUT/
hypermut.html[29]. This tool can distinguish plus-strand
hA3G/F hypermutation, by measuring the number of G to
A changes in the GG and GA dinucleotide context, respec-
tively, and testing for a significant increase (p < 0.05) from
background levels of mutation.
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